ArticleRespirology case reports2026
Impact of Severe COVID-19 on Interstitial Lung Disease in Autoimmune Systemic Diseases.
Article in Respirology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to assess the impact of severe COVID-19 pneumonia on the course of interstitial lung disease (ILD) in autoimmune systemic diseases (ASD). We conducted a multicentre case series of 27 ASD patients (20 systemic sclerosis, 4 rheumatoid arthritis, 1 interstitial pneumonia with autoimmune features, 1 dermatomyositis, 1 eosinophilic granulomatosis with polyangiitis) hospitalised for severe COVID-19. Clinical data, pulmonary function tests and HRCT before and after infection were analysed. Four patients died during acute COVID-19. Among the 23 survivors, 10 developed new symptomatic ILD and 13 showed worsening of pre-existing ILD. Six exhibited significant HRCT progression, including NSIP-to-UIP transition; one developed lung adenocarcinoma. Despite treatment, five more patients died during follow-up from progressive ILD. Overall mortality approached one-third, with systemic sclerosis most affected. Severe COVID-19 may trigger or accelerate ASD-related ILD. The observed NSIP-to-UIP shift highlights a multistep process potentially driven by SARS-CoV-2, underscoring the need for close ILD monitoring in ASD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.